Ferguson Wellman Capital Management Inc. Raises Stock Position in Johnson & Johnson $JNJ

Ferguson Wellman Capital Management Inc. lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 41.0% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 666,675 shares of the company’s stock after purchasing an additional 193,905 shares during the period. Johnson & Johnson comprises approximately 2.1% of Ferguson Wellman Capital Management Inc.’s portfolio, making the stock its 11th largest holding. Ferguson Wellman Capital Management Inc.’s holdings in Johnson & Johnson were worth $176,495,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Auto Owners Insurance Co increased its holdings in Johnson & Johnson by 22,225.6% during the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after purchasing an additional 69,108,368 shares during the period. Capital World Investors acquired a new stake in Johnson & Johnson in the fourth quarter valued at approximately $2,005,942,000. Jupiter Topco LLC purchased a new stake in Johnson & Johnson in the second quarter valued at about $1,967,399,000. Diamant Asset Management Inc. boosted its stake in Johnson & Johnson by 24,436.5% in the 1st quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company’s stock worth $109,338,000 after purchasing an additional 4,454,778 shares in the last quarter. Finally, Capital International Investors raised its stake in Johnson & Johnson by 93.3% in the 4th quarter. Capital International Investors now owns 7,471,031 shares of the company’s stock worth $1,546,130,000 after acquiring an additional 3,605,981 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on JNJ. Scotiabank reissued an “outperform” rating and issued a $305.00 price objective on shares of Johnson & Johnson in a report on Thursday, July 16th. UBS Group reissued a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, September 22nd. Argus set a $300.00 target price on shares of Johnson & Johnson in a research note on Wednesday, July 29th. Royal Bank Of Canada raised their price objective on Johnson & Johnson from $265.00 to $287.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Finally, Weiss Ratings upgraded shares of Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $275.87.

Johnson & Johnson Stock Performance

NYSE JNJ traded down $1.96 during trading on Monday, reaching $254.07. The company’s stock had a trading volume of 3,741,572 shares, compared to its average volume of 7,973,521. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The firm has a market cap of $612.28 billion, a price-to-earnings ratio of 29.43, a P/E/G ratio of 2.52 and a beta of 0.21. The business’s fifty day moving average price is $266.37 and its 200-day moving average price is $248.40. Johnson & Johnson has a twelve month low of $182.94 and a twelve month high of $281.07.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. During the same quarter in the previous year, the firm earned $2.77 earnings per share. The business’s quarterly revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, analysts anticipate that Johnson & Johnson will post 11.54 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend was Tuesday, August 25th. Johnson & Johnson’s payout ratio is presently 62.11%.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 15,000 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Vanessa Broadhurst sold 23,054 shares of the company’s stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the sale, the executive vice president owned 23,003 shares in the company, valued at $5,779,963.81. The trade was a 50.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 87,569 shares of company stock worth $23,064,544. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.